Ponoi II Management, LLC
Follow13F filer, CIK 1746488, San Francisco, CA
Ponoi II Management, LLC reported $130,572,000 across 5 holdings for the quarter ended 2021-03-31, in a 13F-HR filed 2021-05-17.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-21-007095
- Period
- 2021-03-31
- Reported value
- $131M
- Holdings
- 5
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Holdings, Q1 2021
Share positions as resolved from 13F-HR 0000950123-21-007095, largest first. % of portfolio is the value over $130,572,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 1,298,908 | $37.8M | 28.92% | 0 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 1,574,229 | $36.8M | 28.2% | 0 | |||
| RVMDREVOLUTION MEDICINES INC | 685,011 | $31.4M | 24.07% | 0 | Timeline | ||
| NRIXNURIX THERAPEUTICS INC | 686,274 | $21.3M | 16.34% | 0 | Timeline | ||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 145,401 | $3.23M | 2.47% | 0 |
How Q1 2021 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-21-007095 | base | 2021-05-17 | acceptance time not in the bulk data set |